EDIL3 is a novel epithelial-mesenchymal transition (EMT) regulator, promoting angiogenesis, metastasis, and recurrence in HCC by activating ERK and TGF-β signaling [51], and inhibiting anoikis [52]. This evidence concerns the gene EDIL3 and hepatocellular carcinoma.